此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

自体 T 细胞在实体瘤受试者中表达 T 细胞受体 (TCR) 的 I/II 期研究

2026年11月3日 更新者:Alaunos Therapeutics

使用睡美人系统设计的自体 T 细胞的 I/II 期研究,以表达 T 细胞受体 (TCR) 对实体瘤受试者的癌症特异性突变具有反应性

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors. The study ended during Phase I Arm A after 8 subjects were treated. Arm B and Phase II were not initiated, and the maximum tolerated dose or recommended Phase II dose was not determined.

研究概览

详细说明

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors.

Screening was initially conducted under TCR001-002. TCR001-201 Protocol Amendment 4, approved by the IRB on 20 January 2023 and implemented at the site in February 2023, incorporated HLA typing and tumor neoantigen screening into TCR001-201. Eligibility required a matching tumor mutation and HLA restriction represented in the Sponsor's clinical TCR library.

The Phase I part of this study is a prospective, open-label, dose-escalation study of TCR-T cell drug product in patients with progressive or recurrent solid tumors who have failed standard therapy. The Phase II part is a prospective, open-label, single dose portion of the study. The planned Phase II portion was to begin after determination of the maximum tolerated dose or recommended Phase II dose in Phase I. The program closed during Phase I Arm A before that determination. Arm B and Phase II were not initiated, and no subject received interleukin-2 under this study.

Subjects with one of the following histologically confirmed solid tumors will be included:

  • Cohort 1: Gynecologic cancer (e.g., ovarian, endometrial)
  • Cohort 2: Colorectal cancer
  • Cohort 3: Pancreatic cancer
  • Cohort 4: Non-small cell lung cancer (NSCLC); NSCLC includes but is not limited to squamous cell carcinoma, adenosquamous carcinoma or adenocarcinomas
  • Cohort 5: Cholangiocarcinoma

Subject must have a tumor mutation and HLA typing combination that matches to at least one of the following TCRs in the Alaunos' library (mutation & HLA type):

  • KRAS G12D & HLA-A*11:01
  • KRAS G12D & HLA-C*08:02
  • KRAS G12V & HLA-A*11:01
  • KRAS G12V & HLA-C*01:02
  • TP53 R175H & HLA-A*02:01
  • TP53 R175H & HLA-DRB1*13:01
  • TP53 R248W & HLA-A*68:01
  • TP53 Y220C & HLA-A*02:01
  • TP53 Y220C & HLA-DRB3*02:02
  • EGFR E746-A750del & HLA-DPA1*02:01, DPB1*01:01

研究类型

介入性

注册 (实际的)

8

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • MD Anderson Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients who have completed the HLA Typing and Tumor Neoantigen Identification Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA type restriction combination is available in Alaunos' Clinical TCR library

  2. Patients who have previously received at least one line of standard systemic therapy for their advanced/metastatic cancer and have either progressed, recurred, or were intolerant to the previous treatment. Specifically:

    • Subgroup 1. Gynecologic cancers (i.e., ovarian or endometrial):

      1. Ovarian cancer
      2. Endometrial cancer
    • Subgroup 2. Colorectal cancer

    • Subgroup 3. Pancreatic cancer

    • Subgroup 4. Non-small cell lung cancer (NSCLC)

    • Subgroup 5. Cholangiocarcinoma

  3. Patients must have evaluable or measurable disease per RECIST 1.1 with at least one lesion that can be measured that is not the biopsied lesion.

  4. Patients must be able to provide written informed consent.

  5. Patients must be age ≥ 18 years.

  6. Clinical Performance Status of ECOG 0 or 1. Approval from the Alaunos Medical Monitor is required for ECOG of 2.

  7. Patient must be willing and able to provide written informed consent for the long-term follow-up protocol (TCR001-202) for up to 15 years post TCR-T Cell drug product infusion per FDA requirements.

  8. Adequate bone marrow reserves as assessed by the following hematology laboratory criteria:

  9. Adequate major organ system function

  10. A washout period must have elapsed since completion of any prior systemic therapy, and apheresis with guidelines as follows (windows other than what is listed below should be allowed only after consultation with the Medical Monitor); subjects' non-hematologic toxicities from any prior systemic therapy must have recovered to ≤ Grade 1 (with the exception of neuropathy and alopecia) or baseline prior to starting the protocol's therapy.

  11. Patients may have undergone minor surgical procedures or limited-field radiotherapy provided any major organ toxicities have recovered to ≤ Grade 1.

  12. Female patients must not be pregnant or breastfeeding.

Exclusion Criteria:

  1. Patients with known active CNS metastases
  2. Concurrent systemic steroid therapy
  3. Any form of primary immunodeficiency
  4. Patients who have decreased immune competence
  5. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, aldesleukin or bendamustine
  6. Severe chronic respiratory condition
  7. History of a bleeding disorder or unexplained major bleeding diathesis
  8. Arm B Criteria only: Clinically significant patient history which in the judgment of the principal investigator (PI) would compromise the subject's ability to tolerate high-dose aldesleukin;
  9. Any major bronchial occlusion or bleeding not amenable to palliation.
  10. Patients with psychiatric illness/social situations at the time of treatment that would limit compliance with study requirements.
  11. Participants with known active, uncontrolled bacterial, fungal, or viral infection
  12. Patients with a prior history or concurrent malignancy
  13. Active unstable or clinically significant medical condition
  14. History of any major cardiovascular conditions within the past 6 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:TCR-T Cell Drug Product

Phase I: Dose-escalation of TCR-T Cell Drug Product

Phase II: Single dose of TCR-T Cell Drug Product after MTD/RP2D determine in Phase I portion of the study

Phase I:

Ascending dose, single Infusion of TCR+ Cells

Phase II:

Single infusion at the RP2D

实验性的:TCR-T Cell Drug Product with Aldesleukin (IL-2)

Phase I: Dose-escalation of TCR-T Cell Drug Product with Aldesleukin (IL-2)

Phase II: Single dose of TCR-T Cell Drug Product with Aldesleukin (IL-2) after MTD/RP2D determine in Phase I portion of the study

Phase I:

Ascending dose, single Infusion of TCR+ Cells

Phase II:

Single infusion at the RP2D

To support growth and activation of TCR-T cell drug product

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With Treatment-Emergent Adverse Events
大体时间:From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.

Treatment-emergent adverse events (TEAEs) were defined as any adverse event that began or worsened after initiation of lymphodepletion and up to 28 days following TCR-T cell infusion. TEAEs were coded using MedDRA and summarized by system organ class and preferred term, severity, and relationship to study treatment. Participants were followed for delayed or ongoing toxicities for up to 1 year.

From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.
Frequency of Dose Limiting Toxicities
大体时间:From Day 0 to Day 28 post TCR-T cell drug product infusion.

Number of participants experiencing DLTs, defined as specific adverse events attributable to the TCR-T cell drug product occurring within the first 28 days of infusion. DLTs include, but are not limited to, Grade 4 neutropenia lasting ≥ 14 days, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with significant bleeding, and ≥ Grade 3 febrile neutropenia with hemodynamic compromise. Non-hematologic DLTs include Grade 3 or 4 Cytokine Release Syndrome (CRS) that does not improve to Grade ≤ 2 within 72 hours, and Grade 3 Immune-effector cell-associated neurotoxicity syndrome (ICANS) that does not resolve to Grade ≤ 2 within 7 days, among others. The severity of adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

From Day 0 to Day 28 post TCR-T cell drug product infusion.
Determination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
大体时间:From Day 0 to Day 28 post TCR-T cell drug product infusion.

MTD/RP2D determination was planned using accelerated escalation followed by the Bayesian Optimal Interval (BOIN) design and the protocol dose-escalation, de-escalation and stopping rules. Overt-toxicity criteria included 2 or more DLTs and consideration of longer-term toxicity. The trial would stop if the lowest dose was eliminated for overt toxicity. Formal MTD/RP2D determination was not completed because the study closed during Phase I Arm A.

From Day 0 to Day 28 post TCR-T cell drug product infusion.

次要结果测量

结果测量
措施说明
大体时间
Feasibility of TCR-T Cell Drug Product Manufacturing
大体时间:From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks

Number of participants in each mutually exclusive leukapheresis and manufacturing disposition category. A full-scale run is a clinical drug-product manufacturing run; small-scale testing and cell enrichment or cryopreservation are not full-scale runs. All released products were infused. Final cell count and viability of released products are reported in separate outcome measures.

From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks
TCR-T Cell Persistence
大体时间:Baseline through nominal Month 18 post-infusion.

Peripheral-blood TCR-T vector copy number (VCN) was measured by droplet digital PCR (ddPCR; LabCorp Drug Development) in copies per 1 × 10⁶ cells. Visits are nominal. One DL2 participant's nominal Day 28 and Week 6 samples were both collected on Day 44; the Month 18 sample was collected on Day 577. Samples after TCR001-201 exit were collected under TCR001-202 (NCT05292859). Summaries include quantifiable values only; not-detected and below-LLOQ values are excluded. NA indicates no quantifiable result. One post-dose Day 0 sample has identical copies/reaction and copies/mL values to another participant's sample; the copies per 1 × 10⁶ cells values differ. Sampling ended at disease progression, death or program closure.

Baseline through nominal Month 18 post-infusion.
Percent Change in TCR-T Cell Count From Post Dose to Day 28
大体时间:Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.

For each participant, percent change from the highest post-dose VCN (copies per 1 × 10⁶ cells, ddPCR) from Day 0 post-dose through Day 21 to the nominal Day 28 value: ((Day 28 - peak) / peak) × 100. A Day 28 value below the LLOQ was set to 0 (-100%).

Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.
Final T-Cell Count in Released TCR-T Cell Drug Product
大体时间:At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).

Final cell counts from the Certificate of Analysis for the released product administered to each participant. The two rows report total viable cells from the automated cell counter and final murine T-cell receptor-positive (mTCR+) cells from the Content-Calculation method, each in billions of cells. These are manufacturing results, not the administered dose. For participants with more than 1 manufacturing run, only the released lot is used.

At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
Viability of Released TCR-T Cell Drug Product
大体时间:At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).

Percent viability reported on the final Certificate of Analysis for the released TCR-T cell product administered to each participant. One released product per participant is summarized, including the second manufacturing run when that run supplied the infused product.

At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
Protocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample
大体时间:From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.

Per Protocol Section 15.3.4 and SAP Section 4.5.2, duration is the number of days from infusion (Day 0) to the last sample with VCN at or above the assay lower limit of quantification. This is an observed last-quantifiable-sample metric. Sampling stopped at different times because of disease progression, death or program closure, so it does not establish when TCR-T cells disappeared. Later ND or below-LLOQ samples do not extend this metric. Samples from TCR001-202 are included where applicable.

From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Scott Kopetz, MD, PhD、MD Anderson

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年4月4日

初级完成 (实际的)

2023年9月30日

研究完成 (实际的)

2023年10月11日

研究注册日期

首次提交

2021年12月6日

首先提交符合 QC 标准的

2022年1月3日

首次发布 (实际的)

2022年1月18日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅